Acute Myelocytic Leukemia

Search Trials
Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients
Status:
Recruiting
Last Changed:
May 4, 2022
First Changed:
May 4, 2022
Disease(s):
Acute Myeloid Leukemia
Intervention(s):
Venetoclax, AzacitidineVenetoclax, daunorubicin, cytarabine
MAP to Provide Access to Midostaurin, for Patients 18 Years of Age and Older With Newly-diagnosed FLT3-mutated AML and Eligible for Induction and Consolidation Chemotherapy
Status:
Available
Last Changed:
Feb 2, 2022
First Changed:
Feb 2, 2022
Disease(s):
FMS-Like Tyrosine Kinase 3-mutated Acute Myeloid Leukemia
Intervention(s):
midostaurin
Clinical Efficacy and Safety of CD47 Monoclonal Antibody Combined With Azacitidine in the Treatment of Recurrent AML After Transplantation
Status:
Recruiting
Last Changed:
Mar 4, 2022
First Changed:
Mar 4, 2022
Disease(s):
Patients With Recurrent Acute Myelogenous Leukemia After Transplantation
Intervention(s):
CD47 monoclonal antibody
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
Status:
Not yet recruiting
Last Changed:
Feb 4, 2022
First Changed:
Feb 4, 2022
Disease(s):
Acute Myeloid Leukemia in Remission
Intervention(s):
Prospective determination of the clinical utility of measurable residual disease (MRD) testing
PLAT-08: A Study Of SC-DARIC33 In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML
Status:
Recruiting
Last Changed:
Dec 29, 2021
First Changed:
Nov 3, 2021
Disease(s):
Acute Myeloid Leukemia
Intervention(s):
SC-DARIC33

Connect. Empower. Inspire.